NEW YORK (GenomeWeb) – Researchers at the University College London Cancer Institute plan to use Natera's technology to analyze circulating cell-free DNA in a non-small cell lung cancer study with the goal of understanding how the cancers mutate, adapt, and become resistant to therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.